Department of Gastroenterology, the Affiliated Hospital of Qingdao University, Qingdao, China.
Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
Medicine (Baltimore). 2024 Aug 2;103(31):e39195. doi: 10.1097/MD.0000000000039195.
The interstitial pneumonia (IP) linked to vedolizumab (VDZ) in patients with ulcerative colitis (UC) is rare. Prompt diagnosis and treatment can improve patient outcomes.
A 39-year-old man with UC who received VDZ as sole therapy developed symptoms such as chest tightness, cough, and suffocation.
IP was confirmed through pulmonary function tests, chest computed tomography, and bronchoscopic biopsy.
The patient was given methylprednisolone and VDZ cessation.
The patient's symptoms improved and remained symptom-free after nearly 2 years.
VDZ-induced IP should be considered when evaluating pulmonary infections in UC patients treated with VDZ.
接受维得利珠单抗（VDZ）治疗的溃疡性结肠炎（UC）患者发生间质性肺炎（IP）的情况罕见。及时诊断和治疗可改善患者的结局。
一名 39 岁男性，UC 患者，单用 VDZ 治疗后出现胸闷、咳嗽和呼吸困难等症状。
通过肺功能检查、胸部计算机断层扫描和支气管镜活检确诊为 IP。
给予患者甲基泼尼松龙和停用 VDZ。
患者的症状改善，近 2 年后无任何症状。
评估接受 VDZ 治疗的 UC 患者肺部感染时，应考虑 VDZ 诱导的 IP。
